1: Bolin K, Niska PÅ, Pirhonen L, Wasling P, Landtblom AM. The cost-utility of pitolisant as narcolepsy treatment. Acta Neurol Scand. 2019 Dec 14. doi: 10.1111/ane.13202. [Epub ahead of print] PubMed PMID: 31838740.
2: Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2019 Oct 18. pii: zsz252. doi: 10.1093/sleep/zsz252. [Epub ahead of print] PubMed PMID: 31626696.
3: Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group . Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep. 2019 Oct 21;42(11). pii: zsz174. doi: 10.1093/sleep/zsz174. PubMed PMID: 31529094; PubMed Central PMCID: PMC6802569.
4: Fouque C, Martin R, Seguro F, Montastruc JL, de Canecaude C. Splenic Infarction in a Narcoleptic Patient Treated With Methylphenidate, Venlafaxine, and Pitolisant. Ann Pharmacother. 2019 Sep 10:1060028019872795. doi: 10.1177/1060028019872795. [Epub ahead of print] PubMed PMID: 31502855.
5: Scolnick B. Antihistamine agents and pitolisant might be useful for anorexia nervosa. Med Hypotheses. 2019 Nov;132:109342. doi: 10.1016/j.mehy.2019.109342. Epub 2019 Jul 30. PubMed PMID: 31421416.
6: Pullen LC, Picone M, Tan L, Johnston C, Stark H. Cognitive Improvements in Children with Prader-Willi Syndrome Following Pitolisant Treatment-Patient Reports. J Pediatr Pharmacol Ther. 2019 Mar-Apr;24(2):166-171. doi: 10.5863/1551-6776-24.2.166. PubMed PMID: 31019411; PubMed Central PMCID: PMC6478354.
7: Huyts B, Brabant C, Tirelli E. Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol. 2019 May 15;851:63-68. doi: 10.1016/j.ejphar.2019.02.019. Epub 2019 Feb 14. PubMed PMID: 30771351.
8: Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther. 2018 Aug 30;12:2665-2675. doi: 10.2147/DDDT.S101145. eCollection 2018. Review. PubMed PMID: 30214155; PubMed Central PMCID: PMC6124464.
9: Kotańska M, Kuder KJ, Szczepańska K, Sapa J, Kieć-Kononowicz K. The histamine H(3) receptor inverse agonist pitolisant reduces body weight in obese mice. Naunyn Schmiedebergs Arch Pharmacol. 2018 Aug;391(8):875-881. doi: 10.1007/s00210-018-1516-2. Epub 2018 May 25. PubMed PMID: 29802412; PubMed Central PMCID: PMC6061715.
10: Ligneau X, Shah RR, Berrebi-Bertrand I, Mirams GR, Robert P, Landais L, Maison-Blanche P, Faivre JF, Lecomte JM, Schwartz JC. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies. Br J Pharmacol. 2017 Dec;174(23):4449-4463. doi: 10.1111/bph.14047. Epub 2017 Oct 19. PubMed PMID: 28941245; PubMed Central PMCID: PMC5715595.
11: Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep. 2017 Apr 26;9:127-133. doi: 10.2147/NSS.S103462. eCollection 2017. Review. PubMed PMID: 28490912; PubMed Central PMCID: PMC5414617.
12: Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med. 2017 May;33:125-129. doi: 10.1016/j.sleep.2017.01.002. Epub 2017 Feb 11. PubMed PMID: 28449891.
13: Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC; HARMONY-CTP study group. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017 Mar;16(3):200-207. doi: 10.1016/S1474-4422(16)30333-7. Epub 2017 Jan 25. PubMed PMID: 28129985.
14: Baumann CR. Wide implications of a trial on pitolisant for cataplexy. Lancet Neurol. 2017 Mar;16(3):173-174. doi: 10.1016/S1474-4422(16)30398-2. Epub 2017 Jan 25. PubMed PMID: 28129984.
15: ▼Pitolisant for narcolepsy. Drug Ther Bull. 2017 Jan;55(1):6-8. doi: 10.1136/dtb.2017.1.0448. PubMed PMID: 28087755.
16: Brabant C, Charlier Y, Navacerrada MES, Alleva L, Tirelli E. Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice. Eur J Pharmacol. 2016 Nov 15;791:552-559. doi: 10.1016/j.ejphar.2016.08.027. Epub 2016 Aug 26. PubMed PMID: 27568835.
17: Bruhn C. Pitolisant for the treatment of narcolepsy with or without cataplexy. Med Monatsschr Pharm. 2016 Aug;39(8):324-9. Review. German. PubMed PMID: 29984945.
18: Syed YY. Pitolisant: First Global Approval. Drugs. 2016 Sep;76(13):1313-1318. doi: 10.1007/s40265-016-0620-1. Review. PubMed PMID: 27438291.
19: Collart Dutilleul P, Ryvlin P, Kahane P, Vercueil L, Semah F, Biraben A, Schwartz JC, De Seze J, Hirsch E, Collongues N. Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months. Clin Neuropharmacol. 2016 Jul-Aug;39(4):188-93. doi: 10.1097/WNF.0000000000000159. PubMed PMID: 27223666.
20: Dudek M, Kuder K, Kołaczkowski M, Olczyk A, Żmudzka E, Rak A, Bednarski M, Pytka K, Sapa J, Kieć-Kononowicz K. H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metab Brain Dis. 2016 Oct;31(5):1023-9. doi: 10.1007/s11011-016-9840-z. Epub 2016 May 24. PubMed PMID: 27216278; PubMed Central PMCID: PMC5031740.
